Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Resequinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | WRN | Q14191 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resequinil SCHEMBL29375531 | 1.00 | PIK3CD (0.57) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL4890983 | 0.89 | PDE3B (0.54) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL678532 | 0.88 | PIK3CD (0.55) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL4887297 | 0.84 | PIK3CD (0.52) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL4886299 | 0.82 | HSD17B10 (0.54) | MAPTALDH1A1PTPN7BLMWRN | |
| SCHEMBL4891258 | 0.79 | KDM4E (0.42) | MAPTALDH1A1PTPN7BLMWRN | |
| SCHEMBL16067423 | 0.73 | L3MBTL1 (0.72) | MAPTPKMHSD17B10KMT2ANPC1 | |
| SCHEMBL4883414 | 0.71 | ELANE (0.43) | PIK3CDPIK3CBMAPTALDH1A1HPGD | |
| SCHEMBL6437384 | 0.71 | JAK2 (0.46) | ALDH1A1PDE3BPDE3AKDM4ECLK2 | |
| SCHEMBL5752654 | 0.70 | NPC1 (0.39) | MAPTPKMHSD17B10KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-11-06 | — | — | US | claimed |
| EP-1736155-A1 | MEDICINE COMPRISING COMBINATION OF ACETYLCHOLINE ESTERASE INHIBITOR AND 5-SUBSTITUTED 3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1010699-B1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | EP | claimed |
| US-6743803-B2 | SUCH AS ALZHEIMER'S DISEASE AND SCHIZOPHRENIA DUE TO HYPOFUNCTION OF GLUTAMIC ACID RECEPTOR; 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | claimed |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1295883-A1 | MEDICINES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-03-26 | — | — | EP | claimed |
| US-6172079-B1 | BENZODIAZEPINE INVERSE AGONISTS; ALZHEIMER*S DISEASE; ANXIOLYTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS, ANTIEPILEPTIC AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| EP-1010699-A1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2000-06-21 | — | — | EP | claimed |
| US-20230240994-A1 | MEDICAMENT-CONTAINING HOLLOW PARTICLE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230115839-A1 | Methods For Treating Hypersomnia | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11529358-B2 | Treatment of conditions associated with myotonic dystrophy | EMORY UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3791867-A1 | MEDICAMENT-CONTAINING HOLLOW PARTICLE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-20210023091-A1 | TREATMENT OF CONDITIONS ASSOCIATED WITH MYOTONIC DYSTROPHY | EMORY UNIVERSITY | 2021-01-28 | — | — | US | disclosed |
| EP-2886109-B1 | MEDICAMENT-CONTAINING HOLLOW PARTICLE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-6743803-B2 | SUCH AS ALZHEIMER'S DISEASE AND SCHIZOPHRENIA DUE TO HYPOFUNCTION OF GLUTAMIC ACID RECEPTOR; 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295883-A1 | MEDICINES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6277993-B1 | USEFUL AS A BENZODIAZEPINE INVERSE AGONIST, FOR EXAMPLE, AS PSYCHOANALEPTIC DRUG OR DRUG FOR TREATMENT OF DYSMNESIA IN SENILE DEMENTIA OR ALZHEIMER'S DISEASE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6172079-B1 | BENZODIAZEPINE INVERSE AGONISTS; ALZHEIMER*S DISEASE; ANXIOLYTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS, ANTIEPILEPTIC AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1010699-A1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | ACHE, BCHE, CHAT | GABRA1 957/4885GABRG2 1266/4885GABRB3 1163/4885 |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | GRIN1, GRIN2A, GRM2 | GABRA1 48/4885GABRG2 41/4885GABRB3 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.